Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

被引：8

作者：

Atalay, Selma ^{[1
]}

Berends, Sophie E. ^{[2
]}

Groenewoud, Hans M. M. ^{[3
]}

Mathot, Ron A. A. ^{[2
]}

Njoo, David M. ^{[4
]}

Mommers, Johannes M. ^{[5
]}

Ossenkoppele, Paul M. ^{[6
]}

Koetsier, Marjolein I. A. ^{[7
]}

Berends, Maartje A. ^{[8
]}

de Vries, Annick ^{[9
]}

van de Kerkhof, Peter C. M. ^{[1
]}

den Broeder, Alfons A. ^{[10
]}

de Jong, Elke M. G. J. ^{[1
,11
]}

van den Reek, Juul M. P. A. ^{[1
]}

机构：

[1] Radboudumc, Dept Dermatol, Nijmegen Rene Descartesdreef 1, Nijmegen, Netherlands

[2] Acad Med Ctr, Dept Hosp Pharm, Amsterdam, Netherlands

[3] Radboudumc, Radboud Inst Hlth Sci, Dept Hlth Evidence, Nijmegen, Netherlands

[4] Ziekenhuis Grp Twente, Dept Dermatol, Hengelo, Netherlands

[5] Sint Anna Ziekenhuis, Dept Dermatol, Geldrop, Netherlands

[6] Ziekenhuis Grp Twente, Dept Dermatol, Almelo, Netherlands

[7] Gelre Ziekenhuizen, Dept Dermatol, Apeldoorn, Netherlands

[8] Slingelandziekenhuis, Dept Dermatol, Doetinchem, Netherlands

[9] Sanquin Diagnost Serv, Biol Lab, Bioanal, Amsterdam, Netherlands

[10] Sint Maartensklin, Dept Rheumatol, Nijmegen, Netherlands

[11] Radboud Univ Nijmegen, Nijmegen, Netherlands

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2022年 / 33卷 / 05期

关键词：

Psoriasis; adalimumab; etanercept; ustekinumab; dose reduction; dose tapering; MONOCLONAL-ANTIBODIES; IMMUNOGENICITY;

D O I：

10.1080/09546634.2022.2043546

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent overtreatment, and lower risks and costs. However, fear for increased anti-drug antibody (ADA) formation due to interval prolongation of biologics is an important barrier. Objective To investigate the course of serum drug concentrations, ADA levels, and predictors for successful dose reduction of adalimumab, ustekinumab, and etanercept for psoriasis. Methods Patients were randomized to dose reduction (DR) or usual care (UC) and followed for one year. The course and extent of detectable ADA levels were expressed as proportions/relative risks for DR vs. UC. Association of baseline characteristics with successful tapering was investigated with log-binomial regression analysis. Results In total, 118 patients were included. In adalimumab-treated patients, no significant difference in the proportion of patients with relevant ADA levels in DR vs. UC was seen. For ustekinumab, relevant ADA development was absent in both groups. Baseline trough levels were not predictive for successful DR. Conclusions Immunogenicity may not increase by interval prolongation in psoriasis patients with low disease activity. This pilot provides important and reassuring insight into the pharmacological changes after dose tapering of adalimumab, etanercept, and ustekinumab.

引用

页码：2680 / 2684

页数：5

共 15 条

[1] Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study [J].

Atalay, Selma ;

van den Reek, Juul M. P. A. ;

Otero, Marisol E. ;

Njoo, Marcellus D. ;

Mommers, Johannes M. ;

Ossenkoppele, Paul M. ;

Koetsier, Marjolein, I ;

Berends, Maartje M. ;

van de Kerkhof, Peter C. M. ;

Groenewoud, Hans M. M. ;

den Broeder, Alfons A. ;

de Jong, Elke M. G. J. ;

Kievit, Wietske .

ACTA DERMATO-VENEREOLOGICA, 2020, 100 :1-7

[2] Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis A Randomized Clinical Trial [J].

Atalay, Selma ;

van den Reek, Juul M. P. A. ;

den Broeder, Alfons A. ;

van Vugt, Lieke J. ;

Otero, Marisol E. ;

Njoo, Marcellus D. ;

Mommers, Johannes M. ;

Ossenkoppele, Paul M. ;

Koetsier, Marjolein I. ;

Berends, Maartje A. ;

van de Kerkhof, Peter C. M. ;

Groenewoud, Hans M. M. ;

Kievit, Wietske ;

de Jong, Elke M. G. J. .

JAMA DERMATOLOGY, 2020, 156 (04) :393-400

[3] Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab [J].

Bendtzen, Klaus ;

Geborek, Pierre ;

Svenson, Morten ;

Larsson, Lotta ;

Kapetanovic, Meliha C. ;

Saxne, Tore .

ARTHRITIS AND RHEUMATISM, 2006, 54 (12) :3782-3789

[4] Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis [J].

Chiu, Hsien-Yi ;

Wang, Ting-Shun ;

Chan, Chih-Chieh ;

Lin, Sung-Jan ;

Tsai, Tsen-Fang .

ACTA DERMATO-VENEREOLOGICA, 2015, 95 (06) :711-716

[5] Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against Etanercept [J].

Detrez, Iris ;

Brouwers, Els ;

Peeters, Miet ;

Geukens, Nick ;

de Vlam, Kurt ;

Gils, Ann .

JOURNAL OF IMMUNOLOGY, 2016, 196 (06) :2879-2884

[6] Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases [J].

Ducourau, Emilie ;

Mulleman, Denis ;

Paintaud, Gilles ;

Lin, Delphine Chu Miow ;

Lauferon, Francine ;

Ternant, David ;

Watier, Herve ;

Goupille, Philippe .

ARTHRITIS RESEARCH & THERAPY, 2011, 13 (03)

[7] Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis One-Year Follow-up [J].

Menting, Stef P. ;

van Lumig, Paula P. M. ;

de Vries, Anna-Christa Q. ;

van den Reek, Juul M. P. A. ;

van der Kleij, Desiree ;

de Jong, Elke M. G. J. ;

Spuls, Phyllis I. ;

Lecluse, Lidian L. A. .

JAMA DERMATOLOGY, 2014, 150 (02) :130-136

[8] The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study [J].

Moots, Robert J. ;

Xavier, Ricardo M. ;

Mok, Chi Chiu ;

Rahman, Mahboob U. ;

Tsai, Wen-Chan ;

Al-Maini, Mustafa H. ;

Pavelka, Karel ;

Mahgoub, Ehab ;

Kotak, Sameer ;

Korth-Bradley, Joan ;

Pedersen, Ron ;

Mele, Linda ;

Shen, Qi ;

Vlahos, Bonnie .

PLOS ONE, 2017, 12 (04)

[9] Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms [J].

Ordas, Ingrid ;

Mould, Diane R. ;

Feagan, Brian G. ;

Sandborn, William J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (04) :635-646

[10] Maintenance therapy with certolizumab pegol for Crohn's disease [J].

Schreiber, Stefan ;

Khaliq-Kareemi, Mani ;

Lawrance, Ian C. ;

Thomsen, Ole Ostergaard ;

Hanauer, Stephen B. ;

McColm, Juliet ;

Bloomfield, Ralph ;

Sandborn, William J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03) :239-250

← 1 2 →